Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: Global retrospective analysis of clinician- and patient-reported clinical characteristics and humanistic burden of patients with gastroesophageal cancers on first-line treatment

Fig. 6

Drivers of EQ-VAS in patients with GC/GEJC/EAC, HER2 negative/unknown, on first-line treatment. EAC, esophageal adenocarcinoma; ECOG, Eastern Cooperative Oncology Group; EQ-VAS, EuroQol-Visual Analogue Scale; GC, gastric cancer; GEJC, gastroesophageal junction cancer. * p < 0.05, † base category. Gastrointestinal symptoms include indigestion, heartburn, reflux, bloating, flatulence, distended abdomen, early satiety, abdominal discomfort, loss of appetite, unexplained weight loss, melena, dysphagia, and odynophagia. Respiratory symptoms include chest infection, shortness of breath, chest pain, persistent coughing, pleural effusion, sputum. Sickness symptoms include nausea, vomiting, diarrhea. Other symptoms include weakness and fatigue, jaundice, acute bleeding, headaches, anemia, other pain, other

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us